Palopegteriparatide
A once-daily prodrug that releases parathyroid hormone steadily, for adults whose glands no longer make enough
Palopegteriparatide is PTH(1-34), the active fragment of parathyroid hormone, bound to an inert carrier that releases it steadily. Approved as Yorvipath in 2024 for hypoparathyroidism in adults, it let most trial participants stop active vitamin D and high-dose calcium.
Manufacturer's recommended dosing (FDA label): Start 18 µg; adjust in 3 µg steps to a maximum of 30 µg, Once daily, as a single injection, Subcutaneous Details ↓
Recommended Dosing
Manufacturer's recommended dosing (FDA label)
From the prescribing information. Other doses studied, if any, are in the full dosing data below.
Work out syringe units → · New to syringes? · All dosing data ↓ · Full Palopegteriparatide dosage guide
What is it?
In hypoparathyroidism the parathyroid glands make too little hormone, so blood calcium falls. Calcium and active vitamin D relieve that but do not restore normal parathyroid hormone physiology. Palopegteriparatide replaces the hormone itself: PTH(1-34) bound to an inert carrier and designed to release it steadily.
The steady release is the point. Measured across a day, PTH stayed within the estimated normal range for all 24 hours at 12 to 33 µg, with blood calcium and phosphate near normal and urine calcium stable; the label gives the released hormone a half-life of about 60 hours.
In the phase 3 PaTHway trial, 84 adults were randomized three to one to the drug or placebo. At 26 weeks, 79% on the drug met the main goal against 5% on placebo. At one year, 81% had normal blood calcium without conventional therapy and none needed active vitamin D; at two years, 97% of those still taking it were independent of conventional therapy. Kidney function improved: eGFR rose by a mean 9.3 mL/min/1.73 m² over the first year in a post hoc analysis.
Results outside the main trial look similar. A Japanese trial had 12 of 13 adults meeting the same combined goal at 26 weeks, and a Greek real-world cohort of 92 patients saw urine calcium fall and 58% stop calcium and alfacalcidol within about a month. Bone, which turns over too slowly in this disease, became more active; density fell in the first six months and then settled, still above average.
Yorvipath was approved in the US on August 9, 2024, for adults; it was not studied in the acute form straight after surgery. The dose starts at 18 µg and moves in 3 µg steps, with blood calcium checked 7 to 10 days after each change. It is always one injection, because two make the dose more variable. Switching from PTH(1-84) usually needs adjustment: in one series 80% changed dose within a month.
Mechanism of Action
Palopegteriparatide is a prodrug: PTH(1-34) attached through the TransCon linker to an inert carrier, releasing the hormone continuously so it acts like the body's own PTH (label).
Steady release
The linker cleaves on its own at body conditions, releasing PTH(1-34); steady state is reached after about 7 days (label).
PTH1 receptor
Released PTH acts on PTH1R in bone and kidney, raising calcium and lowering phosphate.
Kidney and vitamin D
It increases calcium reabsorption and phosphate excretion in the kidney and drives active vitamin D synthesis, so calcium absorption from the gut rises (label).
Published Research
The studies behind palopegteriparatide, read from their PubMed abstracts.
PaTH Forward: phase 2, 59 adults
Adults with hypoparathyroidism took 15, 18 or 21 µg a day or placebo for four weeks, then an adjusted dose of 6 to 60 µg a day. By week 26, 91% of those on the drug no longer needed active vitamin D and took 500 mg or less of calcium a day.
PaTHway: phase 3, 26 weeks, 84 adults
Adults were randomized three to one to the drug, starting at 18 µg a day, or placebo. At week 26, 79% on the drug met the composite primary goal, which required normal blood calcium, against 5% on placebo; 93% no longer needed conventional therapy. Adverse events: 82% against 100%, mostly mild or moderate.
PaTHway at one year
Of 82 adults who received the drug, 78 completed week 52. At week 52, 81% had normal blood calcium without conventional therapy, 95% were independent of conventional therapy, and none needed active vitamin D.
PaTHway at two years: kidney function
At week 104, 76 of 82 remained in the open-label extension; 82% of them had normal blood calcium and 97% were independent of conventional therapy. This post hoc analysis reported sustained improvement in eGFR, a measure of kidney filtration.
Case report: stopping after three years
A 62-year-old man with hypoparathyroidism after surgery stopped the drug after three years and restarted calcium and calcitriol at adjusted doses. The report describes a rebound effect after stopping.
PaTHway: kidney function at one year
In a post hoc analysis of PaTHway, eGFR rose by a mean 9.3 mL/min/1.73 m² over 52 weeks, and by 11.5 in those starting below 60; no kidney stones were reported on the drug through week 52.
PaTHway Japan: 13 adults
In a single-arm Japanese trial, 12 of 13 adults met the combined goal of normal calcium without active vitamin D or therapeutic calcium at 26 weeks, and 11 of 12 at 52 weeks; no adverse event led to stopping.
Bone over three years
In the PaTH Forward extension, bone turnover rose at first and then stabilised through week 162; bone density, high to begin with in hypoparathyroidism, fell mostly in the first 26 weeks and on average stayed above normal.
A day of steady PTH
At 12 to 33 µg a day, PTH stayed within the estimated normal range across 24 hours, with serum calcium and phosphate near or within normal and urine calcium stable in every 4-hour collection.
PaTH REAL: 92 patients in Greece
In a prospective real-world cohort treated for a median 6.5 months, calcium rose from 8.14 to 8.99 mg/dL, 24-hour urine calcium fell from 246 to 165 mg, and 58% stopped calcium supplements and alfacalcidol after a median of 30 days.
Switching from PTH(1-84)
In 40 patients switched from recombinant PTH(1-84) to a standard 18 µg starting dose, 80% needed a dose change within a month, 38% down to 9-15 µg and 43% up to 21-27 µg.
Dosing Data
Yorvipath starts at 18 µg once a day under the skin and is adjusted in 3 µg steps, up to 30 µg, to keep blood calcium normal without active vitamin D or high-dose calcium.
Educational information, not medical advice. Each dose above is tagged with its source: an approved label, a published human study, animal data, or amounts reported by users. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose. Full medical disclaimer.
→ Full Palopegteriparatide dosage guide — the Yorvipath label's titration
What a Buyer Needs to Know
What is sold, how it is mixed, stored and taken, and what is known about its safety, quality and legal status. Each part names its source. Where we have none, it says unknown.
What is sold
The approved product, as its label describes it:
- Yorvipath (palopegteriparatide injection): Injection: single-patient-use prefilled pen. Forms the label lists: single-patient-use prefilled pens.
Source: Yorvipath (palopegteriparatide injection) label, section 3 (DailyMed version 9, effective August 12, 2026).
Mixing a vial: a worked example
Nothing to mix: the label gives Yorvipath (palopegteriparatide injection) as single-patient-use prefilled pens, ready to use.
Source: Yorvipath (palopegteriparatide injection) label, sections 2, 3 and 16 (DailyMed version 9, effective August 12, 2026).
Storage before and after mixing
Before mixing or first use: “Store away from heat.” “Until first use, store YORVIPATH in the refrigerator between 2°C to 8°C (36°F to 46°F).” “Follow the Instructions for Use to administer YORVIPATH using pen and needle: YORVIPATH must be refrigerated at 2°C to 8°C (36°F to 46°F) until first use.”
After mixing or first use: “After first use, store YORVIPATH for 14 days at room temperature below 30°C (86°F).” “After each use, remove the needle and put the pen cap on to protect from light.” “Discard the prefilled pen 14 days after first use.”
Source: Yorvipath (palopegteriparatide injection) label, sections 16 and 2 (DailyMed version 9, effective August 12, 2026).
How it is taken
As the approved label gives it: Subcutaneous (Once daily, as a single injection; Label: hypoparathyroidism in adults (calcium at least 7.8 mg/dL and normal vitamin D before starting)).
Source: Manufacturer's recommended dosing (FDA label): the route and frequency of each row in Dosing Data below.
What to expect, and when
How long it stays in the body: a half-life of about 60 hours for the PTH released from the prodrug. After about five half-lives almost none is left.
How long the doses were given: Label: hypoparathyroidism in adults (calcium at least 7.8 mg/dL and normal vitamin D before starting): Ongoing; calcium checked every 4 to 6 weeks once stable.
When effects appear: unknown; no source on this page gives a time to effect for Palopegteriparatide. Results reported in the studies are under Published Research.
Source: half-life: Yorvipath prescribing information, section 12.3 (DailyMed set a1fa23fd-c434-443e-9a17-5750578c8602, effective August 12, 2026; read October 2, 2026); Manufacturer's recommended dosing (FDA label), the duration of each row in Dosing Data below.
Side effects, and when to stop or get help
From the Side Effects section: Adverse events were common in both groups in PaTHway, 82% on the drug and 100% on placebo, mostly mild or moderate; A case report describes a rebound effect after stopping the drug. Full list and cautions ↓
When to stop or get help: unknown; the label's warnings summary we read gives no rule for stopping Palopegteriparatide. Treat a severe or unexpected reaction as a reason to stop and see a doctor.
Source: the Side Effects section below (“From the trials above”).
Interactions
Unknown: a PubMed search for human interaction studies of Palopegteriparatide (reviewed 2026-10-06) found none. Unknown is not the same as safe to combine.
Every peptide's record, with its source: the interaction matrix.
Checking what you bought
Unknown: no published independent test of Palopegteriparatide products is in our lab-results database yet, so how products sold under this name measure up is not known.
To read a certificate of analysis, paste it into the COA decoder. Trust & Verification explains what independent testing can and cannot show.
Legal status
US: FDA Approved (Approved in the US as Yorvipath (palopegteriparatide injection), NDA 216490, approved August 9, 2024, for hypoparathyroidism in adults (Drugs@FDA via openFDA and the Yorvipath label, read October 2, 2026)). Sport: Not on the 2026 List.
Country by country ↓ · Regulatory tracker
Source: this entry's approval status and the WADA Prohibited List, as in Legal Status below.
Side Effects & Contraindications
Reported Side Effects
From the trials above.
Contraindications & Cautions
From the Yorvipath label (DailyMed, effective August 12, 2026).
Legal Status
Palopegteriparatide is approved in the US as Yorvipath; ChEMBL records its first approval anywhere in 2023.
Frequently Asked Questions
?What is palopegteriparatide?
A once-daily prodrug of PTH(1-34), the active fragment of parathyroid hormone, bound to a carrier that releases it steadily. It is sold in the US as Yorvipath for hypoparathyroidism in adults.
?How is it different from teriparatide?
Both deliver PTH(1-34). Teriparatide is a brief daily pulse for osteoporosis; palopegteriparatide releases it steadily, the released hormone lasting about 60 hours, to replace what is missing.
?What dose is used?
The label starts at 18 micrograms once daily and adjusts in 3 microgram steps by blood calcium, to a maximum of 30 micrograms, always as a single injection.
?What happens if it is stopped?
A 2025 case report describes a rebound effect after stopping; the label warns that serious high and low blood calcium have occurred.
References
- [fda] FDA. Drugs@FDA (openFDA): YORVIPATH (palopegteriparatide) injection, NDA 216490, original approval August 9, 2024, prescription. Read October 2, 2026.
- [fda] FDA. Yorvipath (palopegteriparatide) injection US prescribing information (DailyMed set a1fa23fd-c434-443e-9a17-5750578c8602, version 9, effective August 12, 2026). Read October 2, 2026.
- [clinical-trial] Khan AA, et al. "PaTH Forward: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of TransCon PTH in Adult Hypoparathyroidism." J Clin Endocrinol Metab, 2022;107(1):e372-e385. PMID: 34347093.
- [clinical-trial] Khan AA, et al. "Efficacy and Safety of Parathyroid Hormone Replacement With TransCon PTH in Hypoparathyroidism: 26-Week Results From the Phase 3 PaTHway Trial." J Bone Miner Res, 2023;38(1):14-25. PMID: 36271471.
- [clinical-trial] Clarke BL, et al. "Efficacy and Safety of TransCon PTH in Adults With Hypoparathyroidism: 52-Week Results From the Phase 3 PaTHway Trial." J Clin Endocrinol Metab, 2025;110(4):951-960. PMID: 39376010.
- [pubmed] Rejnmark L, et al. "Sustained improvement in renal function with palopegteriparatide in adults with chronic hypoparathyroidism: 2-year results from the phase 3 PaTHway-trial." J Bone Miner Res, 2026;41(9):922-933. PMID: 42166177.
- [pubmed] Naciu AM, et al. "Rebound Effect Following the Discontinuation of Palopegteriparatide." Calcif Tissue Int, 2025;116(1):121. PMID: 40956444.
- [pubmed] Karpf DB, et al. "A Randomized Double-Blind Placebo-Controlled First-In-Human Phase 1 Trial of TransCon PTH in Healthy Adults." J Bone Miner Res, 2020;35(8):1430-1440. PMID: 32212275.
- [pubmed] Rejnmark L, et al. "Palopegteriparatide Treatment Improves Renal Function in Adults with Chronic Hypoparathyroidism: 1-Year Results from the Phase 3 PaTHway Trial." Adv Ther, 2024;41(6):2500-2518. PMID: 38691316.
- [pubmed] Ashida K, et al. "Palopegteriparatide in Japanese adults with hypoparathyroidism: 52-week results from the phase 3 PaTHway Japan trial." Endocr J, 2026;73(2):275-289. PMID: 41260697.
- [pubmed] Rubin MR, et al. "Palopegteriparatide for adults with chronic hypoparathyroidism: skeletal dynamics through 3 years of the phase 2 PaTH forward trial." J Bone Miner Res, 2026;41(10):1069-1079. PMID: 41636590.
- [pubmed] Khan AA, et al. "Pharmacodynamics of sustained levels of PTH following palopegteriparatide treatment in adults with hypoparathyroidism." J Endocr Soc, 2026;10(7):bvag098. PMID: 42440695.
- [pubmed] Yavropoulou MP, et al. "Real-world data for effectiveness and safety of palopegteriparatide in patients with chronic hypoparathyroidism: the PaTH REAL study." Eur J Endocrinol, 2026;195(2):372-383. PMID: 42656047.
- [pubmed] Siggelkow H, et al. "Switch From rhPTH1-84 to TransCon PTH With Individual Dose Adjustment in Adult Hypoparathyroidism-4-Week Results." J Endocr Soc, 2025;9(9):bvaf113. PMID: 40709359.
Sources & Citations
Studies were read from their PubMed abstracts; the Yorvipath label was read October 6, 2026 and re-read October 27, 2026 (DailyMed version 9, effective August 12, 2026; sections 1, 2, 5, 6 and 12 unchanged since the first reading).
Medical Disclaimer: This content is for educational and informational purposes only. It is not medical advice, and nothing here is an instruction to obtain or use any compound. Talk to a licensed clinician about your own situation.